Highland Medical P.C. | Hematology Oncology Associates of Rockland

Research site

(Unclaimed)

Location

255 Fifth Avenue, Nyack, New York, United States of America

Site insights

Top conditions

Top treatments

Everolimus

Carboplatin

Ibrutinib

ASA404

Xentuzumab

Paclitaxel

cyclophosphamide

PF-07850327

Ixabepilone

Vinorelbine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 19 total trials

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physici...

Enrolling

Breast Neoplasms

Drug: Liposomal doxorubicin

Drug: Sacituzumab tirumotecan

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling

Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

Drug: Venetoclax

Drug: Ibrutinib

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling

Advanced Breast Cancer

Drug: Fulvestrant

Drug: ARV-471

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia (ENERGY)

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling

Warm Autoimmune Hemolytic Anemia

Drug: M281

Drug: Placebo

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants wit...

Active, not recruiting

Colorectal Cancer

Biological: MK-4830

Biological: Pembrolizumab/Quavonlimab

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with prim...

Enrolling

Primary Immune Thrombocytopenia

Biological: PF-06835375